By Ohio Governor Mike DeWine joined Bayer and JobsOhio today to announce Bayer’s plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio.
Bayer is expected to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility’s construction.
“Bayer is a globally respected life sciences company that could have chosen to build this new facility anywhere in the United States — and it chose Ohio,” said Governor Mike DeWine. “This project firmly solidifies Ohio’s place among global biomanufacturing leaders as a destination for life sciences investment.”
Building on more than $7 billion in U.S. pharma R&D and manufacturing spending over the past five years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market.
“Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment,” said Bayer CEO Bill Anderson. “The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.”
The flexible, modular campus will be designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support Bayer’s growing portfolio in oncology, cardiovascular and renal care. By building in Ohio, Bayer strengthens the reliability of America’s medicine supply.
“Bayer’s $2.2 billion investment is a direct result of Ohio’s commitment to innovation and infrastructure and creating the environment for businesses to succeed,” said Senator Bernie Moreno. “We beat out many other states for this project. When completed, it could employ around 600 people making medicine here. Ohio keeps proving it is the best place in America to do business, and this does not happen without strong leadership.”
The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031. A second module for drug product manufacturing is planned to follow in 2034. The new site will complement Bayer’s U.S. pharmaceuticals headquarters in Whippany, N.J., and its other sites in Pittsburgh, Pa.; Berkeley, Calif.; Cambridge, Mass.; Research Triangle Park, N.C.; and San Diego, California.
Support the New Americans magazine to continue to serve our community with precise news that affects the new American, immigrant and refugee community. https://paypal.com/donate/? Dr;/.hosted_button_id=8LHFS78NRNJJY&source=url
